


Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-58 (cancelled).


59 (currently amended). A peptide comprising at least one peptide fragment of the general formula I:



wherein

X¹, X⁵, X⁶, X⁷ and X⁹ are independently selected from amino acids and X¹ is the N-terminal amino acid of the fragment and X⁹ is the C-terminal amino acid of the fragment;

X² is selected from the group consisting of (a) amino acids of the general formula IIa




wherein n is an integer in the range from 0 to 3; R¹ is selected from the group consisting of optionally substituted five-, six- and seven-membered non-aromatic rings; R² is selected from the group consisting of hydrogen and C₁₋₄-alkyl; or,

R¹ and R² together with the carbon atom to which they are bound form an optionally substituted cyclopentyl, cyclohexyl, cycloheptyl or decahydronaphthalenyl ring;

USSN - 09/743,329

and


(b) N-substituted amino acids of the general formula IIb



wherein n and R¹ are as defined above;

X³ and X⁸ are each independently selected from the group consisting of amino acids having hydrophobic side chains and amino acids having hydrophobic N-substituents;


X⁴ is selected from the group consisting of (a) amino acids of the general formula IIIa



wherein m is an integer in the range from 1 to 3, and Y is selected from the group consisting of OH, SH, NH₂, CONH₂, COOH and OPO₃H;


and

(b) N-substituted amino acids of the general formula IIb



wherein m and Y are as defined above.

60 (previously presented). A peptide according to claim 59, wherein X² is selected from L-amino acids of the general formula IIc



wherein n is 1 or 2 and R¹ is selected from the group consisting of optionally substituted five-, six- and seven-membered non-aromatic rings.

61 (previously presented). A peptide according to claim 59, wherein X³ and X⁸ are each independently selected from the group consisting of D- and L-phenylalanine, D- and L-tryptophan, D- and L-tyrosine, D- and L-histidine, β-2-naphthyl-L-alanine, β-2-naphthyl-D-alanine, β-1-naphthyl-L-alanine, β-1-naphthyl-D-alanine, N-(2,3-dimethoxybenzyl)glycine, N-(3-indolyloethyl)glycine, N-benzylglycine, -(methylnaphthalyl)glycine, N-(2,2-diphenylethyl)glycine, -(indanyl)glycine, N-(2-ethyl-2-pyridinyl)glycine and N-(4-methoxyphenylethyl)glycine.

62 (previously presented). A peptide according to claim 59,

wherein the peptide fragment is selected from the group consisting of dChaFsrYLWS, SLChaFsQYLWS, eChaFsyYLWS, DChaFsrYLWS, DChaFSrYLWS, dChaFSrYLWS, tChaFsrYLWS, dChaFsrYL²nAS, DChaFsRYLWS, DChaFsrYL¹nAS, eChaFsYYLWS, D-Cha-F-s-r-L-L-W-h, D-Cha-F-s-r-Cha-L-W-l, D-Cha-F-s-r-Y-L-Nal-h, D-Cha-F-s-r-DMB-f-TRA-MEA, D-Cha-F-s-r-DMB-f-Bzl-MEA, D-Cha-F-s-r-DMB-f-AMN-MEA and D-Cha-F-s-r-DMB-f-DMB-l

wherein Cha designates β -cyclohexyl-L-alanine, ¹nA designates β -1-naphthyl-L-alanine, ²nA designates β -2-naphthyl-L-alanine, capital letters designate L-amino acids, lower case letters designate D-amino acids, β A designates β -alanine, DMB designates N-(2,3-dimethoxybenzyl)glycine, TRA designates N-(3-indolylethyl)glycine, MEA designates N-(2-methoxyethyl)glycine, Bzl designates N-benzylglycine and AMN designates N-(methylnaphthalyl)glycine.

63 (previously presented). A peptide according to claim 59, which comprises more than one peptide fragment of the general formula I.

64 (previously presented). A peptide according to claim 63, wherein each of the peptide fragments are attached to a common scaffold.

65 (previously presented). A pharmaceutical composition comprising a peptide according to claim 59.

66 (previously presented). A method of treating cancer in a mammal comprising administering an effective amount of a peptide according to claim 59.

67-68 (cancelled).

69 (new). The peptide of claim 59 in which X₂ is Cha.

70 (new). The peptide of claim 69 in which X₃ is F.

71 (new). The peptide of claim 70 in which X₁ is d, D, e, E, t or T.

72 (new). The peptide of claim 71 in which X₁ is d or D.

73 (new). The peptide of claim 72 in which X_4 is D-Serine (s).

74 (new). The peptide of claim 73 in which X_5 is R, r, Y, y, Q or q.

75 (new). The peptide of claim 74 in which X_5 is D-Arginine (r).

76 (new). The peptide of claim 75 in which X_6 to X_9 are Y-L-W-S.

77 (new). The peptide of claim 75 in which X_6 is DMB and X_7 is f.

78 (new). The peptide of claim 75 in which X_9 is MEA.

79 (new). A peptide according to claim 59, wherein n is 1.

80 (new). A peptide according to claim 79 where R^1 is selected from the group consisting of cyclopentyl, cyclohexyl and cycloheptyl.

81 (new). A peptide according to claim 80, wherein R^1 is cyclohexyl.

82 (new). A peptide according to claim 59, wherein X^2 is selected from N-substituted amino acids of the general formula IIb, wherein n is 1 or 2.

83 (new). A peptide according to claim 82, wherein n is 1.

84 (new). A peptide according to claim 83 wherein R^1 is selected from the group consisting of cyclopentyl, cyclohexyl and cycloheptyl.

85 (new). A peptide according to claim 84, wherein R^1 is cyclohexyl.

86 (new). A peptide according to claim 59 wherein the hydrophobicity constant (π) of the side chain or the N-substituent of the amino acid in the X^3 position is at least 0.5.

87 (new). A peptide according to claim 59 wherein the hydrophobicity constant (π) of the side chain or the N-substituent of the amino acid in the X^8 position is at least 0.5.

88 (new). A peptide according to claim 59, wherein X^3 and X^8 are each independently selected from amino acids with aromatic side chains or aromatic N-substituents.

89 (new). A peptide according to claim 88, wherein X^3 and X^8 are each independently selected from amino acids with aromatic side chains.

90 (new). A peptide according to claim 61, wherein X^3 and X^8 are each independently selected from the group consisting of D- and L-phenylalanine, D- and L-tryptophan, D- and L-tyrosine, D- and L-histidine, β -2-naphthyl-L-alanine, β -2-naphthyl-D-alanine, β -1-naphthyl-L-alanine and β -1-naphthyl-D-alanine.

91 (new). A peptide according to claim 90, wherein X^3 is L-phenylalanine.

92 (new). A peptide according to claim 59 where X^8 is selected from the group consisting of L-tryptophan, N-(2,3-dimethoxybenzyl)glycine, N-(3-indolyethyl)glycine, N-benzylglycine, N-(methylnaphthalyl)glycine, N-(2,2-diphenylethyl)glycine, N-(indanyl)glycine, N-(2-ethyl-2-pyridinyl)glycine and N-(4-methoxyphenylethyl)glycine.

93 (new). A peptide according to claim 92, wherein X^8 is selected from the group consisting of L-tryptophan, N-benzylglycine, N-(methylnaphthalyl)glycine and N-(2,3-dimethoxybenzyl)glycine.

94 (new). A peptide according to claim 59 wherein X^4 is selected from the group consisting of L-serine, D-serine, L-cysteine, D-cysteine, N-(hydroxymethyl)glycine and N-(methylthiol)glycine.

95 (new). A peptide according to claim 94, wherein X^4 is selected from the group consisting of L-serine, D-serine, L-cysteine and D-cysteine.

96 (new). A peptide according to claim 95, wherein X^4 is D-serine.